Theravance (THRX +20.6%) tops the leader board as a staff report suggests Breo — a COPD...


Theravance (THRX +20.6%) tops the leader board as a staff report suggests Breo — a COPD treatment the company is developing with GlaxoSmithKline (GSK +3.1%) — could be set for approval by the FDA which will evaluate a recommendation Wednesday. There were some questions about side effects which Citi and UBS analysts said were expected. THRX will get royalties of 15% on the first $3B in sales and 5% thereafter. 

From other sites
Comments (1)
  • Michael Bryant
    , contributor
    Comments (6944) | Send Message
     
    $2.79 billion??? (THRX) is worth $2.79 billion, and it does not even have a drug on the market???? If is fails FDA approval, stock has a lot to lose.
    15 Apr 2013, 07:41 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs